Fig. 3

Differential expression of rate-limiting enzyme genes and transporter genes involved in a nucleotide synthesis, b energy (ATP) synthesis and lipid production, c uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) synthesis, d asparagine metabolism, e proline production, f serine production, and g anti-oxidation factor synthesis. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; COAD, colon adenocarcinoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; PRAD, prostate adenocarcinoma; THCA, thyroid carcinoma; PPAT, phosphoribosyl pyrophosphate amidotransferase; APRT, adenine phosphoribosyltransferase; ADA, adenosine deaminase; ADK, adenosine kinase; HPRT1, hypoxanthine phosphoribosyltransferase 1; SLC28A1, solute carrier family 28 member 1; CAD, carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase; UCK1, uridine–cytidine kinase 1; UCKl1, uridine–cytidine kinase 1 like 1; UPP1, uridine phosphorylase 1; UPRT, uracil phosphoribosyltransferase homolog; HK1, hexokinase 1; HKDC1, hexokinase domain containing 1; GCK, glucokinase; PFKL, phosphofructokinase, liver type; PFKM, phosphofructokinase, muscle; PKLR, pyruvate kinase, liver and RBC; PKM2, pyruvate kinase, muscle; ATP5A1, ATP synthase, H⁺ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle; SLC2A1, solute carrier family 2 member 1; ACACA, acetyl-CoA carboxylase alpha; ACACB, acetyl-CoA carboxylase beta; FASN, fatty acid synthase; FABP1, fatty acid binding protein 1; APOBR, apolipoprotein B receptor; CD36, CD36 molecule; CXCL16, C-X-C motif chemokine ligand 16; ILDR1, immunoglobulin like domain containing receptor 1; LDLR, low density lipoprotein receptor; LRP1, LDL receptor related protein 1; OLR1, oxidized low density lipoprotein receptor 1; SCARB1, scavenger receptor class B member 1; STAB 1, stabilin 1; STAB 2, stabilin 2; VLDLR, very low density lipoprotein receptor; GFPT1, glutamine-fructose-6-phosphate transaminase 1; GNPNAT1, glucosamine-phosphate N-acetyltransferase 1; PGM3, phosphoglucomutase 3; UAP1, UDP-N-acetylglucosamine pyrophosphorylase 1; UAP1L1, UDP-N-acetylglucosamine pyrophosphorylase 1 like 1; ASNS, asparagine synthetase; ALDH18A1, aldehyde dehydrogenase 18 family member A1; PYCR1, pyrroline-5-carboxylate reductase 1; ARG1, arginase 1; OAT, ornithine aminotransferase; PQLC2, PQ loop repeat containing 2; ASS1, argininosuccinate synthase 1; PSAT1, phosphoserine aminotransferase 1; PSPH, phosphoserine phosphatase; SERINC1, serine incorporator 1; GCLC, glutamate–cysteine ligase catalytic subunit; GCLM, glutamate–cysteine ligase modifier subunit; GSS, glutathione synthetase; TXN, thioredoxin; TXNRD1, thioredoxin reductase 1